Ignite Creation Date:
2024-05-05 @ 11:07 AM
Last Modification Date:
2024-10-26 @ 9:02 AM
Study NCT ID:
NCT00002236
Status:
COMPLETED
Last Update Posted:
2005-06-24
First Post:
1999-11-02
Brief Title:
A Study to Find the Best Dosing Schedule for Delavirdine Zidovudine and Indinavir in HIV-Positive Patients
Sponsor:
Pharmacia and Upjohn
Organization:
NIH AIDS Clinical Trials Information Service
Study Overview
Official Title:
An Open-Label Parallel Group Pilot Study of Safety Tolerance Pharmacokinetics and Pharmacodynamics of BID and TID Regimens of Delavirdine Mesylate Zidovudine and Indinavir Sulfate in HIV-1 Infected Individuals
Status:
COMPLETED
Status Verified Date:
2000-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to see whether it is better to take delavirdine DLV plus indinavir IDV plus zidovudine ZDV twice a day or three times a day
Detailed Description:
Patients are divided into 2 treatment groups the groups are balanced with respect to viral load Group A receives ZDV DLV and IDV 3 times daily Group B receives ZDV DLV and IDV 2 times daily Patients are evaluated for changes from baseline in viral load and CD4 cell count
Study Oversight
Has Oversight DMC:
Is a FDA Regulated Drug?:
Is a FDA Regulated Device?:
Is an Unapproved Device?:
Is a PPSD?:
Is a US Export?:
Is an FDA AA801 Violation?:
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| M33310072 | None | None | None |